On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved updated dosing information for nivolumab (Opdivo®). Nivolumab is now the first FDA-approved PD-1 inhibitor that offers a flexible dosing option of every two weeks at 240 mg or every four weeks at 480 mg for most approved indications. The manufacturer, Bristol-Meyers Squibb, maintains a list of approved indications. Nivolumab has also been approved for 30-minute infusions across all indications, reducing previous administration times by 50%.
Nivolumab has been approved for a number of indications to treat cancers, including hepatocellular carcinoma, colorectal cancers, advanced or metastatic bladder cancer, and more. Stay up to date on emerging FDA approvals through ONS Voice.